Azadeh Golipour is a senior leader with global experience and proven track record in cell and gene therapy process development, analytical development and GMP manufacturing. She is a CMC subject matter expert with ability to provide and execute CMC strategies from early-stage through late-stage product development. Azadeh is experienced in progressing novel therapies to regulatory filings and leading CMC interactions with global regulatory authorities.

Azadeh joined AVROBIO in 2016; during this period, Azadeh designed and implemented AVROBIO’s platform plato^®. Azadeh has also built and led multiple teams during her time at AVROBIO.

Prior to AVROBIO, Azadeh spent time at CCRM, a catalyst for commercializing regenerative medicine-based technologies and cell and gene therapies. CCRM enables product development through its unique translational platforms and process development and manufacturing capabilities. During her time at CCRM, Azadeh led the due diligence, business planning and program leadership for two successful company concepts developing iPSC-derived cell therapies as part of CCRM’s company incubation program. Both of these companies attracted funding from venture capitalists and were spun out of CCRM.

Azadeh holds a PhD in molecular genetics from University of Toronto (Canada) and has published multiple articles, including two first-author articles in the prestigious journal Cell, Stem Cell and one article in the prestigious journal Nature. Azadeh’s landmark articles on reprogramming stem cells have been cited more than 1,000 times.